Menu
Back to Journals » Transplant Research and Risk Management » Volume 7
Cardiac allograft immune activation: current perspectives
Authors Chang D, Kobashigawa JA
Received 12 July 2014
Accepted for publication 26 August 2014
Published 18 December 2014 Volume 2015:7 Pages 13—22
DOI https://doi.org/10.2147/TRRM.S71055
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 4
Editor who approved publication: Professor Qing Yi
Video abstract presented by David Chang and Jon Kobashigawa.
Views: 72
David Chang, Jon Kobashigawa
Cedars-Sinai Heart Institute, Los Angeles, CA, USA
Abstract: Heart transplant remains the most durable option for end-stage heart disease. Cardiac allograft immune activation and heart transplant rejection remain among the main complications limiting graft and recipient survival. Mediators of the immune system can cause different forms of rejection post-heart transplant. Types of heart transplant rejection include hyperacute rejection, cellular rejection, antibody-mediated rejection, and chronic rejection. In this review, we will summarize the innate and adaptive immune responses which influence the post-heart transplant recipient. Different forms of rejection and their clinical presentation, detection, and immune monitoring will be discussed. Treatment of heart transplant rejection will be examined. We will discuss potential treatment strategies for preventing rejection post-transplant in immunologically high-risk patients with antibody sensitization.
Keywords: heart transplant, innate immunity, adaptive immunity, rejection, immunosuppression
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.